Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TBI and metabolism-based cyclophosphamide for hematological malignancy
NCT00317785Phase 2Completed
- Sponsor
- Fred Hutchinson Cancer Center
- Start
- May 2005
- Primary completion
- Nov 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of cyclophosphamide in chronic myelogenous leukemia (CML), acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), myelodysplastic syndrome (MDS), lymphoma, sponsored by Fred Hutchinson Cancer Center. Started May 2005; status: completed.
02
Drugs
cyclophosphamide
03
Conditions
chronic myelogenous leukemia (CML)acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)myelodysplastic syndrome (MDS)lymphoma
Beyond the preview
Go deeper on NCT00317785.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00317785.